Copyright
©2014 Baishideng Publishing Group Inc.
World J Gastroenterol. Jul 21, 2014; 20(27): 8796-8806
Published online Jul 21, 2014. doi: 10.3748/wjg.v20.i27.8796
Published online Jul 21, 2014. doi: 10.3748/wjg.v20.i27.8796
Table 3 Adverse events for lubiprostone phase III irritable bowel syndrome with constipation studies
| Lubiprostone | Placebo | Lubiprostone | |
| 12 wk | 12 wk | 36 wk | |
| Serious | 1% | 1% | 1.90% |
| Treatment related | 22% | 21% | 25.40% |
| Nausea | 8% | 4% | 11% |
| Diarrhea | 6% | 4% | 11% |
| Abdominal distension | 2% | 2% | 3.70% |
| Discontinuation due to ADR | 5% | 7% | 4% |
- Citation: Wall GC, Bryant GA, Bottenberg MM, Maki ED, Miesner AR. Irritable bowel syndrome: A concise review of current treatment concepts. World J Gastroenterol 2014; 20(27): 8796-8806
- URL: https://www.wjgnet.com/1007-9327/full/v20/i27/8796.htm
- DOI: https://dx.doi.org/10.3748/wjg.v20.i27.8796